Literature DB >> 28196338

Telomerase and telomere biology in hematological diseases: A new therapeutic target.

Alessandro Allegra1, Vanessa Innao2, Giuseppa Penna2, Demetrio Gerace2, Andrea G Allegra2, Caterina Musolino2.   

Abstract

Telomeres are structures confined at the ends of eukaryotic chromosomes. With each cell division, telomeric repeats are lost because DNA polymerases are incapable to fully duplicate the very ends of linear chromosomes. Loss of repeats causes cell senescence, and apoptosis. Telomerase neutralizes loss of telomeric sequences by adding telomere repeats at the 3' telomeric overhang. Telomere biology is frequently associated with human cancer and dysfunctional telomeres have been proved to participate to genetic instability. This review covers the information on telomerase expression and genetic alterations in the most relevant types of hematological diseases. Telomere erosion hampers the capability of hematopoietic stem cells to effectively replicate, clinically resulting in bone marrow failure. Furthermore, telomerase mutations are genetic risk factors for the occurrence of some hematologic cancers. New discoveries in telomere structure and telomerase functions have led to an increasing interest in targeting telomeres and telomerase in anti-cancer therapy.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aplastic anemia; Genetic instability; Hematological malignancies; Hematopoietic system; Leukemia; Telomerase; Telomere

Mesh:

Substances:

Year:  2017        PMID: 28196338     DOI: 10.1016/j.leukres.2017.02.002

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

Review 1.  Telomere Length and Hematological Disorders: A Review.

Authors:  Beatriz Maria Dias Nogueira; Caio Bezerra Machado; Raquel Carvalho Montenegro; Maria Elisabete Amaral DE Moraes; Caroline Aquino Moreira-Nunes
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

2.  Activated carbon N-acetylcysteine microcapsule protects against nonalcoholic fatty liver disease in young rats via activating telomerase and inhibiting apoptosis.

Authors:  Tingting Shi; Xingxin Yang; Hongping Zhou; Jianjun Xi; Jingjing Sun; Yunling Ke; Jiankang Zhang; Yidan Shao; Xiaojie Jiang; Xuwang Pan; Shourong Liu; Rangxiao Zhuang
Journal:  PLoS One       Date:  2018-01-11       Impact factor: 3.240

3.  Dual roles of TRF1 in tethering telomeres to the nuclear envelope and protecting them from fusion during meiosis.

Authors:  Lina Wang; Zhaowei Tu; Chao Liu; Hongbin Liu; Philipp Kaldis; Zijiang Chen; Wei Li
Journal:  Cell Death Differ       Date:  2018-01-08       Impact factor: 15.828

Review 4.  Nanomedicines: A Potential Treatment for Blood Disorder Diseases.

Authors:  Nan Zhang; Ming-Yuan Wei; Qiang Ma
Journal:  Front Bioeng Biotechnol       Date:  2019-11-28

Review 5.  Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs.

Authors:  Vanessa Innao; Vincenzo Rizzo; Andrea Gaetano Allegra; Caterina Musolino; Alessandro Allegra
Journal:  Curr Oncol       Date:  2020-12-25       Impact factor: 3.677

6.  Association of telomere length and telomerase methylation with n-3 fatty acids in preschool children with obesity.

Authors:  Xuanyi Liu; Xiaozhou Liu; Qiaoyu Shi; Xiuqin Fan; Kemin Qi
Journal:  BMC Pediatr       Date:  2021-01-07       Impact factor: 2.125

7.  Transcriptomic Analysis of Conserved Telomere Maintenance Component 1 (CTC1) and Its Association with Leukemia.

Authors:  Saadiya Zia; Netasha Khan; Komal Tehreem; Nazia Rehman; Rokayya Sami; Roua S Baty; Faris J Tayeb; Majed N Almashjary; Nouf H Alsubhi; Ghadeer I Alrefaei; Ramla Shahid
Journal:  J Clin Med       Date:  2022-09-29       Impact factor: 4.964

8.  Bone marrow-derived mesenchymal stem/stromal cells in patients with acute myeloid leukemia reveal transcriptome alterations and deficiency in cellular vitality.

Authors:  Leisheng Zhang; Ying Chi; Yimeng Wei; Wenxia Zhang; Fuxu Wang; Lei Zhang; Linglin Zou; Baoquan Song; Xing Zhao; Zhongchao Han
Journal:  Stem Cell Res Ther       Date:  2021-06-26       Impact factor: 6.832

9.  Telomere shortening in breast cancer cells (MCF7) under treatment with low doses of the benzylisoquinoline alkaloid chelidonine.

Authors:  Sakineh Kazemi Noureini; Leili Fatemi; Michael Wink
Journal:  PLoS One       Date:  2018-10-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.